Why publish the framework instead of keeping it proprietary?

Because the value is not the checklist — it is the judgment applied to it. Publishing the structure lets a board see exactly how a recommendation is formed before commissioning one, and lets an internal team run the first pass themselves.

Who is the framework written for?

The person who has to decide whether to commit $500,000, $5 million, or $50 million to a scientific opportunity: founders, investors, licensors, corporate development teams, and boards. It is deliberately not written for bench scientists or for consumers.

Does every dimension have to pass?

No. The framework exists to identify which dimension is the binding constraint, whether that constraint is fixable, and what it costs to fix — a more useful output than a pass/fail score.

How does a Continuum evaluation end?

In a single written verdict — proceed, proceed with conditions, defer pending a specified test, or decline — together with the evidence that would reverse it. Every evaluation answers one question at the end: what is the decision?

Continuum

Innovative

Life Sciences Division

THE METHOD · NINE DIMENSIONS · ONE RECOMMENDATION

The Continuum Translational Assessment Framework™Nine dimensions. One recommendation. The same structure every time.

Almost all scientific content online is written either for scientists or for consumers. Very little is written for the person who has to decide whether to commit $500,000, $5 million, or $50 million to a scientific opportunity. This framework is the method Continuum Innovative applies to that decision — published openly, so a board can see exactly how the judgment is formed before commissioning it. Authored and applied personally by Geno Marcovici, Ph.D., DABAAHP.

Request an evaluation See the framework applied

9: Assessment dimensions
4: Decision verdicts
1: Structure, every time
30 yrs: Judgment behind it

01Why a framework

A named, repeatable method — not an opinion delivered case by case.

Most costly commercial mistakes in life science are scientific mistakes that were never caught in time. They are rarely caught late because the science was hard. They are caught late because nobody ran the same nine questions, in the same order, before the money moved.

The Continuum Translational Assessment Framework™ fixes that order. Every evaluation Continuum produces follows the identical structure, which makes two things possible: findings become comparable across opportunities, and a board can see the reasoning rather than only the conclusion.

It is deliberately weighted toward translation. Biology that cannot be delivered, protected, registered, and differentiated is not an asset — it is a paper. Four of the nine dimensions exist specifically to catch that gap.

Framework authored by Geno Marcovici, Ph.D., DABAAHP — Founder & Chief Scientific Officer, Continuum Innovative, LLC · Life Sciences Division. Applied across 30 years of formulation development, 30+ peer-reviewed publications, and commercialization in 25 countries.

02The nine dimensions

The Continuum Translational Assessment Framework™

Assessed in this order, every time. Earlier dimensions are cheaper to test than later ones, so a fatal flaw surfaces before the diligence budget is spent.

Biological plausibility

Is the proposed mechanism consistent with what is actually known about the biology — or does it require the physiology to behave in a way it has never been shown to behave?

What we look at: Mechanism named at the level of a specific target, pathway, or cell population; consistency with established human physiology; absence of a required miracle step.
Where deals fail: A mechanism that only works in a press release. Plausibility is the cheapest test to run and the one most often skipped.

Mechanistic evidence

Has the mechanism been demonstrated, or merely asserted? Demonstrated where — in silico, in a cell line, in an animal model, in human tissue, in humans?

What we look at: Direct target engagement data; dose-response; independent replication; whether the effect survives translation out of the model system.
Where deals fail: In vitro activity at concentrations that cannot be achieved in living tissue. The most common single failure we encounter.

Quality of experimental evidence

Would the trial design survive a hostile expert reading it? Randomisation, blinding, control selection, powering, endpoint pre-specification, attrition, and who paid for it.

What we look at: Pre-registration; primary vs. post-hoc endpoints; blinding integrity; investigator independence; publication in a journal with real peer review.
Where deals fail: A positive study that was designed to be positive. Effect size and confidence interval matter more than the p-value.

Translational feasibility

Can the effect be delivered to the site of action, in a stable form, at commercial cost, in the intended format?

What we look at: Delivery vehicle and penetration data; formulation stability; supply chain and raw-material integrity; cost of goods at realistic volume.
Where deals fail: A molecule that works and a product that cannot. Feasibility is where most licensing deals quietly die.

Commercial differentiation

Against the incumbent standard of care and the current shelf, is the difference material to the person paying — or only to the inventor?

What we look at: Head-to-head comparison against incumbents; magnitude of benefit a real user would notice; clarity of the claim that can lawfully be made.
Where deals fail: Parity dressed as novelty. If the differentiation cannot be stated in one sentence a buyer repeats, it does not exist.

IP defensibility

Does the intellectual property actually protect the commercial thing being sold, in the jurisdictions where it will be sold?

What we look at: Claim scope vs. product-as-sold; prior art exposure; family coverage in target markets; remaining term; freedom to operate.
Where deals fail: A granted patent whose claims do not cover the product. Grant is not protection; claim language is.

Regulatory complexity

Which regulatory classification does this actually fall into in each target market, and what does that pathway cost in time, money, and claim latitude?

What we look at: Classification per market (cosmetic, supplement, medical device, drug); substantiation dossier required; GCC and EU registration realities; claim ceiling.
Where deals fail: A drug claim on a cosmetic registration. In the GCC this is a market-entry stopper, not a paperwork issue.

Investment risk

What is the realistic distribution of outcomes, what kills this, and what is the earliest cheap experiment that would tell you?

What we look at: Named failure modes ranked by probability; capital at risk before the next decision gate; counterparty and distributor risk; the cheapest disconfirming test.
Where deals fail: Diligence that models upside and never names the kill condition.

Overall recommendation

One verdict, in writing, with the reasoning attached — and the conditions under which the verdict would change.

What we look at: A single verdict: proceed, proceed with conditions, defer pending a specified test, or decline — plus what evidence would reverse it.
Where deals fail: An assessment that leaves the decision back with the board. The deliverable is a decision, not a literature review.

03The output

Four verdicts. One of them, in writing.

Proceed

The science holds, the translation path is real, and the protection is aligned with the product. Move, and move quickly.

Proceed with conditions

Fundable, but only against named conditions — a formulation study, a claim narrowing, a milestone-based deal structure, an escrowed payment.

Defer pending a specified test

One inexpensive experiment stands between uncertainty and a decision. Run it before committing capital, not after.

Decline

A structural defect no amount of capital fixes. Said plainly, in writing, with the reason on record.

The closing question

Every Continuum evaluation ends by answering one question: what is the decision?

Not a literature summary. Not a list of considerations. A verdict, the reasoning behind it, and the specific evidence that would reverse it.

04The framework applied

Worked examples

Flagship evaluation

How to Evaluate a Hair Growth Ingredient Before Licensing It

The full framework run against a real category: mechanism, deliverability, trial design, IP claims, claim substantiation, effect size, and who already passed on it.

Read the evaluation →

Dimension 06 in practice

Patent estate — claim scope against product-as-sold

What defensible protection looks like when the claims actually cover the commercial product, across five mechanism families.

See the estate →

Dimensions 07 & 08 in practice

GCC regulatory classification and distributor risk

Registration pathways, claim ceilings, and counterparty exposure across UAE, Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman.

See the market view →

Engagement formats

How the framework is commissioned

Single-asset assessment, portfolio triage, licensing diligence, and standing advisory — each returning the same nine-dimension structure.

See engagements →

05Questions about the method

Frequently asked

What is the Continuum Translational Assessment Framework™?: It is the nine-dimension structure Continuum Innovative applies to every scientific opportunity it evaluates: biological plausibility, mechanistic evidence, quality of experimental evidence, translational feasibility, commercial differentiation, IP defensibility, regulatory complexity, investment risk, and an overall recommendation. Each dimension is assessed in the same order, in every engagement, so findings are comparable across opportunities and across time.
Why publish the framework instead of keeping it proprietary?: Because the value is not the checklist — it is the judgment applied to it. Publishing the structure lets a board see exactly how a recommendation is formed before commissioning one, and lets an internal team run the first pass themselves. The organizations that need an independent verdict come to us anyway.
Who is the framework written for?: The person who has to decide whether to commit $500,000, $5 million, or $50 million to a scientific opportunity: founders, investors, licensors, corporate development teams, and boards. It is deliberately not written for bench scientists or for consumers.
Does every dimension have to pass?: No. Very few opportunities score well on all nine. The framework exists to identify which dimension is the binding constraint, whether that constraint is fixable, and what it costs to fix — which is a different and far more useful output than a pass/fail score.
How does the framework end?: In a single written verdict — proceed, proceed with conditions, defer pending a specified test, or decline — together with the evidence that would reverse it. Every Continuum evaluation answers one question at the end: what is the decision?

Have the framework run against your opportunity.

Selective engagements only, led personally by Dr. Marcovici. If the answer is that you should decline, you will be told that plainly — which is usually the most valuable output there is.

Request an evaluation Credentials brief